School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy; Nanomedicine Center NANOMIB, University of Milano-Bicocca, 20126 Milano, Italy.
REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Politécnico do Porto, Rua Dr. António Bernardino de Almeida, 431, 4249-015 Porto, Portugal.
Phytomedicine. 2018 Mar 15;42:233-244. doi: 10.1016/j.phymed.2018.03.053. Epub 2018 Mar 19.
Multi-target drugs have gained significant recognition for the treatment of multifactorial diseases such as depression. Under a screening study of multi-potent medicinal plants with claimed antidepressant-like activity, the phenolic-rich Annona muricata aqueous extract (AE) emerged as a moderate monoamine oxidase A (hMAO-A) inhibitor and a strong hydrogen peroxide (HO) scavenger.
In order to protect this extract from gastrointestinal biotransformation and to improve its permeability across the blood-brain barrier (BBB), four phospholipid nanoformulations of liposomes and phytosomes functionalized with a peptide ligand promoting BBB crossing were produced.
AE and nanoformulations were characterized by HPLC-DAD-ESI-MS, HPLC-DAD, spectrophotometric, fluorescence and dynamic light scattering methods. Cytotoxicity and permeability studies were carried out using an in vitro transwell model of the BBB, composed of immortalized human microvascular endothelial cells (hCMEC/D3), and in vitro hMAO-A inhibition and HO scavenging activities were performed with all samples.
The encapsulation/binding of AE was more efficient with phytosomes, while liposomes were more stable, displaying a slower extract release over time. In general, phytosomes were less toxic than liposomes in hCMEC/D3 cells and, when present, cholesterol improved the permeability across the cell monolayer of all tested nanoformulations. All nanoformulations conserved the antioxidant potential of AE, while phosphatidylcholine interfered with MAO-A inhibition assay.
Overall, phytosome formulations registered the best performance in terms of binding efficiency, enzyme inhibition and scavenging activity, thus representing a promising multipotent phenolic-rich nanoshuttle for future in vivo depression treatment.
多靶点药物在治疗抑郁症等多因素疾病方面得到了广泛认可。在对具有声称抗抑郁样活性的多效药用植物进行筛选研究时,富含酚类的安农慕拉托果水提物(AE)表现出中等单胺氧化酶 A(hMAO-A)抑制剂和强过氧化氢(HO)清除剂的特性。
为了保护这种提取物免受胃肠道生物转化,并提高其穿过血脑屏障(BBB)的通透性,制备了四种功能化有促进 BBB 穿越肽配体的脂质体和植物磷脂体纳米制剂。
采用 HPLC-DAD-ESI-MS、HPLC-DAD、分光光度法、荧光法和动态光散射法对 AE 和纳米制剂进行了表征。采用由永生化人微血管内皮细胞(hCMEC/D3)组成的体外 BBB 转染模型进行细胞毒性和通透性研究,并对所有样品进行体外 hMAO-A 抑制和 HO 清除活性研究。
AE 的包封/结合更有效,而脂质体更稳定,随着时间的推移,提取物的释放速度更慢。一般来说,植物磷脂体在 hCMEC/D3 细胞中的毒性低于脂质体,而胆固醇的存在则提高了所有测试的纳米制剂穿过细胞单层的通透性。所有纳米制剂均保留了 AE 的抗氧化潜力,而磷脂酰胆碱则干扰了 MAO-A 抑制测定。
总体而言,植物磷脂体制剂在结合效率、酶抑制和清除活性方面表现最佳,因此代表了一种有前途的多效酚类纳米载体,可用于未来的抑郁症体内治疗。